The major factors that are expected to be driving the genotyping assay market are technological advancements and the decreasing prices of DNA sequencing. The increasing incidence of genetic diseases and rising awareness of personalized medicine, growing importance of genotyping in drug development, and the increasing demand for bioinformatics solutions in data analysis are also expected to promote market growth in the coming years.
The objective of the report is to define, describe, and forecast the genotyping assay market size based on product & service, technology, application, end user, and region.
Request Sample Report : https://www.marketsandmarkets.com/requestsampleNew.asp?id=249958595
MarketsandMarkets forecasts the Genotyping Assay market to grow from USD 11.8 billion in 2018 to USD 31.9 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 22.0% during the forecast period.
Restraining Factors:
🔽 The high cost of tools is expected to hamper the market growth to a certain extent during the forecast period.
Drivers:
🔽 Technological Advancements and Decreasing Prices of DNA Sequencing
🔽 Increasing Incidence of Genetic Diseases and Rising Awareness on
Personalized Medicine
🔽Growing Importance of Genotyping in Drug Development
🔽 Increasing Demand for Bioinformatics Solutions in Data Analysis
Genotyping Market, By Application :
🔽 Pharmacogenomics
🔽 Diagnostic & Personalized Medicine
🔽 Agricultural Biotechnology
🔽 Animal Genetics
🔽 Other Applications (Prenatal Testing, Human Forensics, Microbial Genomic Studies, and Aquaculture Breeding Studies)
North America account for the largest market size during the forecast period.
North America is expected to hold the largest market size in the global genotyping market during the forecast period, followed by the European region. The increasing adoption of technologically advanced genotyping products, the high healthcare expenditure, presence of advanced healthcare infrastructure, highly developed healthcare systems in the US and Canada, large number of genotyping-based R&D projects
Key Players:
Illumina (US), Thermo Fisher Scientific (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US).
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249958595